KSHV-induced oncogenesis
- PMID: 21348069
- Bookshelf ID: NBK47373
KSHV-induced oncogenesis
Excerpt
Human infection by KSHV is associated with the development of at least three proliferative disorders: Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and a subset of multicentric Castleman’s disease (MCD). In keeping with the classification of KSHV as a lymphotropic (γ2) herpesvirus, two of these (PEL and MCD) are primary disorders of the B cell lineage. The third, KS, is a more complex lesion driven by proliferation of cells of endothelial lineage. KSHV is the second human γ-herpesvirus to be linked to neoplasia (EBV being the first). As such, many notions about how KSHV engenders these lesions have been heavily influenced by paradigms derived from the study of EBV-induced malignancies. In EBV, the viral latency program is powerfully immortalizing in vitro, and is thought to be the principal genetic program driving virus-related tumorigenesis. Lytic infection, while presumed important for dissemination of infection to target cells early in infection (and following lytic reactivation at later times), is not thought to play a direct role in the histogenesis of the tumors. As we shall see, although many parallels indeed exist with EBV, the distinctive features of the KSHV-associated diseases makes routine extrapolation from other viral models an enterprise to be undertaken with caution. In this chapter, we will review the biology of the KSHV-associated malignancies and consider the cellular and molecular mechanisms by which KSHV infection contributes to their pathogenesis.
Copyright © Cambridge University Press 2007.
Sections
Similar articles
-
Activated Nrf2 Interacts with Kaposi's Sarcoma-Associated Herpesvirus Latency Protein LANA-1 and Host Protein KAP1 To Mediate Global Lytic Gene Repression.J Virol. 2015 Aug;89(15):7874-92. doi: 10.1128/JVI.00895-15. Epub 2015 May 20. J Virol. 2015. PMID: 25995248 Free PMC article.
-
Pathology of Kaposi's Sarcoma-Associated Herpesvirus Infection.Front Microbiol. 2011 Aug 25;2:175. doi: 10.3389/fmicb.2011.00175. eCollection 2011. Front Microbiol. 2011. PMID: 21904536 Free PMC article.
-
Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.mBio. 2017 Oct 10;8(5):e00917-17. doi: 10.1128/mBio.00917-17. mBio. 2017. PMID: 29018115 Free PMC article.
-
Regulation of KSHV Latency and Lytic Reactivation.Viruses. 2020 Sep 17;12(9):1034. doi: 10.3390/v12091034. Viruses. 2020. PMID: 32957532 Free PMC article. Review.
-
Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.Adv Exp Med Biol. 2018;1045:357-376. doi: 10.1007/978-981-10-7230-7_16. Adv Exp Med Biol. 2018. PMID: 29896675 Review.
References
-
- Aluigi M. G., Albini A., Carlone S., et al. KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of Kaposi’s sarcoma. Res. Virol. 1996;147(5):267–275. - PubMed
-
- An J., Lichtenstein A. K., Brent G., Rettig M. B. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 2002;99(2):649–654. - PubMed
-
- An J., Sun Y., Sun R., Rettig M. B. Kaposi’s sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003;22(22):3371–3385. - PubMed
-
- Aoki Y., Jaffe E. S., Chang Y., et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034–4043. - PubMed
-
- Aoki Y., Yarchoan R., Braun J., Iwamoto A., Tosato G. Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood. 2000;96(4):1599–1601. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials